Detalles de la búsqueda
1.
Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data.
BMC Cancer
; 21(1): 291, 2021 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33740926
2.
Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis.
BMC Nephrol
; 14: 88, 2013 Apr 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-23594621
3.
Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT).
J Neurol
; 270(4): 2096-2105, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36598575
4.
Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG.
BMJ Open
; 13(1): e066445, 2023 01 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-36720569
5.
Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort study.
BMC Nephrol
; 13: 140, 2012 Oct 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-23106934
6.
Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients.
Tumori
; 95(2): 219-26, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19579869
7.
Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison.
Curr Med Res Opin
; 35(3): 479-487, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30086654
8.
Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia.
Appl Health Econ Health Policy
; 17(4): 555-567, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31168745
9.
Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet.
J Med Econ
; 16(9): 1154-62, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23869940
10.
A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries.
Appl Health Econ Health Policy
; 10(2): 127-38, 2012 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22268372
11.
Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy.
Pharmacoeconomics
; 28(11): 1041-54, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20936886
Resultados
1 -
11
de 11
1
Próxima >
>>